top of page
News, Events and Updates
Search
Anavex Life Sciences Reports Fiscal 2020 1st Quarter Financial Results
Feb 6, 2020
Anavex Life Sciences Announces Fast Track Designation Granted by US FDA for ANAVEX®2-73 Development
Feb 3, 2020
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, 2/6/2020
Jan 30, 2020
Anavex Life Sciences Announces Achievement of Enrollment Target for ANAVEX®2-73 Phase 2 PDD Trial
Jan 27, 2020
Anavex Life Sciences Issued New US Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders
Jan 8, 2020
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Update
Dec 16, 2019
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Resultson Monday December 16, 2019
Dec 10, 2019
Anavex Life Sciences Presents ANAVEX®2-73 Data at 12th Clinical Trials on CTAD 2019 Conference
Dec 4, 2019
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73
Nov 14, 2019
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in Rett Syndrome
Nov 6, 2019
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Study in Early Alzheimer’s Disease
Oct 8, 2019
17
18
19
20
21
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
